During the year under review, seven (7) investors briefing sessions were held comprising two regular semi-annual briefing sessions, plus additional two (2) special dialogues. The investors briefing sessions also included three (3) one-on-one meetings with Senior Management, typically led by the GMD and/or the Chief Financial Officer of Duopharma Biotech.